Cadence's Acetavance gets priority review

The FDA has granted Cadence Pharmaceuticals priority review for its Acetavance NDA. Acetavance (intravenous acetaminophen) is being reviewed for the treatment of acute pain and fever in adults and children. The FDA has issued an action date for the NDA of November 13, 2009. Cadence release

Suggested Articles

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.

Going from being the CSO of Bristol Myers Squibb to running one of the biggest cancer research organizations in the world is a major career shift.

Hahn made the commitment in a speech that called on the FDA to learn from the crisis to enact lasting policies that accelerate drug development.